Busca avançada
Ano de início
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Genotype and phenotype spectrum of NRAS germline variants

Texto completo
Mostrar menos -
Altmueller, Franziska ; Lissewski, Christina ; Bertola, Debora ; Flex, Elisabetta ; Stark, Zornitza ; Spranger, Stephanie ; Baynam, Gareth ; Buscarilli, Michelle ; Dyack, Sarah ; Gillis, Jane ; Yntema, Helger G. ; Pantaleoni, Francesca ; van Loon, Rosa L. E. ; MacKay, Sara ; Mina, Kym ; Schanze, Ina ; Tan, Tiong Yang ; Walsh, Maie ; White, Susan M. ; Niewisch, Marena R. ; Garcia-Minaur, Sixto ; Plaza, Diego ; Ahmadian, Mohammad Reza ; Cave, Helene ; Tartaglia, Marco ; Zenker, Martin
Número total de Autores: 26
Tipo de documento: Artigo Científico
Fonte: European Journal of Human Genetics; v. 25, n. 7, p. 823-831, JUN 2017.
Citações Web of Science: 7

RASopathies comprise a group of disorders clinically characterized by short stature, heart defects, facial dysmorphism, and varying degrees of intellectual disability and cancer predisposition. They are caused by germline variants in genes encoding key components or modulators of the highly conserved RAS-MAPK signalling pathway that lead to dysregulation of cell signal transmission. Germline changes in the genes encoding members of the RAS subfamily of GTPases are rare and associated with variable phenotypes of the RASopathy spectrum, ranging from Costello syndrome (HRAS variants) to Noonan and Cardiofaciocutaneous syndromes (KRAS variants). A small number of RASopathy cases with disease-causing germline NRAS alterations have been reported. Affected individuals exhibited features fitting Noonan syndrome, and the observed germline variants differed from the typical oncogenic NRAS changes occurring as somatic events in tumours. Here we describe 19 new cases with RASopathy due to disease-causing variants in NRAS. Importantly, four of them harbored missense changes affecting Gly12, which was previously described to occur exclusively in cancer. The phenotype in our cohort was variable but well within the RASopathy spectrum. Further, one of the patients (c. 35G > A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c. 34G > C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour. With this report, we expand the genotype and phenotype spectrum of RASopathy-associated germline NRAS variants and provide evidence that NRAS variants do not spare the cancer-associated mutation hotspots. (AU)

Processo FAPESP: 11/17299-3 - Estudo clínico e molecular de pacientes com síndromes de Noonan e Noonan-like: caracterização fenotípica e pesquisa de novas alterações causais
Beneficiário:Débora Romeo Bertola
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 13/08028-1 - CEGH-CEL - Centro de Estudos do Genoma Humano e de Células-Tronco
Beneficiário:Mayana Zatz
Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs